title: Use of in-silico assays to characterize the ADMET profile and identify potential therapeutic targets of fusarochromanone, a novel anti-cancer agent.
abstract: OBJECTIVE
  For 30 years nature has provided a plethora of natural products with potential meaningful anti-cancer activity. Fusarochromanone (FC101a) is a small molecule fungal metabolite exhibiting potent in-vitro growth inhibitory effects and is capable of inducing apoptosis, suppressing angiogenesis and tumorigenesis, and inhibiting endothelial cell growth in multiple cancer cell lines. Despite all we know regarding FC101a, the mechanism of action and molecular target(s) of this compound have remained an enigma. Furthermore, modest in-vivo activity has been documented and requires addressing.
  
  
  METHODS
  Early stage pharmacokinetics (PK) assessment is vital to successful drug development. Herein, we aimed to use in-silico assays to i) characterize an in-depth ADMET profile of FC101a and ii) to probe for possible therapeutic targets. Two-dimensional SDF files of FC101a and 13 analogs were introduced into ADMET Predictor Version 7.1 that parses the structures in order to calculate molecular descriptors, which are used to estimate ADMET properties. Calculated ADMET values were analyzed and subjected to multiple drug-like indices, delivering a PK profile of each analog. To probe for possible targets, a total of 49 proteins were introduced into SYBYL-X Version 2.0 platform and the deepest binding pocket of each protein was virtually docked with parent compound, FC101a; with the negative control, FC101b; and with the model compound, kynurenine.
  
  
  RESULTS
  Each analog showed promising ADMET qualities, although FC101 Oxazole was identified as the most optimized analog. Despite FC101a having a desirable ADME and toxicity profile, areas of concern were identified and must be addressed in-vitro. These include potential mutagenic properties and estrogen receptor toxicity. We provide potential avenues medicinal chemists could use to achieve higher effective permeation, higher blood brain barrier (BBB) penetration, and higher aqueous solubility in FC101a. Molecular docking assays revealed procaspase-8 - cFLIP(L) complex as a potential biological target and led to proposed mechanisms of action by which FC101a facilitates procaspase-8 heterodimerization, thereby increasing proteolytic activity and up regulating extrinsic apoptosis.
  
  
  CONCLUSIONS
  Our data revealed both potential mechanisms of action and a promising ADMET profile of FC101a. These attributes render FC101a a promising lead candidate for development into a low toxic anti-cancer agent effective against a broad range of cancers.
authors.affiliation: Department of Chemistry and Physics, LSU-Shreveport, One University Place, 71115, Shreveport, LA, USA. madison.elsaadi@gmail.com.
authors.forename: Madison Wynne
authors.initials: MW
authors.lastname: El-Saadi
authors.affiliation: Department of Biological Science, LSU-Shreveport, 71115, Shreveport, LA, USA. Tara.Williams-Hart@lsus.edu.
authors.forename: Tara
authors.initials: T
authors.lastname: Williams-Hart
authors.affiliation: Department of Chemistry and Physics, LSU-Shreveport, One University Place, 71115, Shreveport, LA, USA. brian.salvatore@lsus.edu.
authors.forename: Brian A
authors.initials: BA
authors.lastname: Salvatore
authors.affiliation: Department of Chemistry and Physics, LSU-Shreveport, One University Place, 71115, Shreveport, LA, USA. emahdavi@lsus.edu.
authors.forename: Elahe
authors.initials: E
authors.lastname: Mahdavian
keywords: ADMET; Apoptosis pathway; Drug design; Drug optimization; In-silico fishing; Molecular docking; Pharmacokinetic
references.citation: J Pharm Pharmacol. 1997 Jul;49(7):682-6
references.pmid: 9255711
references.citation: In Silico Pharmacol. 2013 Aug 08;1:12
references.pmid: 25505657
references.citation: Clin Pharmacol Ther. 2004 Aug;76(2):167-77
references.pmid: 15289793
references.citation: Nat Rev Drug Discov. 2003 Mar;2(3):192-204
references.pmid: 12612645
references.citation: Curr Pharm Des. 2007;13(34):3454-70
references.pmid: 18220783
references.citation: AAPS J. 2014 Sep;16(5):1085-96
references.pmid: 25004821
references.citation: J Comb Chem. 1999 Jan;1(1):55-68
references.pmid: 10746014
references.citation: Drug Metab Dispos. 2010 Aug;38(8):1362-70
references.pmid: 20423955
references.citation: J Med Chem. 2002 Jun 6;45(12):2615-23
references.pmid: 12036371
references.citation: Curr Cancer Drug Targets. 2008 Feb;8(1):37-46
references.pmid: 18288942
references.citation: J Pharm Sci. 2001 Jun;90(6):749-84
references.pmid: 11357178
references.citation: J Nat Prod. 2012 Mar 23;75(3):311-35
references.pmid: 22316239
references.citation: J Mol Graph Model. 2010 Jun;28(8):899-903
references.pmid: 20427217
references.citation: J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89
references.pmid: 15977639
references.citation: Int J Biochem Cell Biol. 2010 Feb;42(2):210-3
references.pmid: 19932761
references.citation: Adv Drug Deliv Rev. 2001 Mar 1;46(1-3):3-26
references.pmid: 11259830
references.citation: J Med Chem. 2009 Nov 12;52(21):6752-6
references.pmid: 19827778
references.citation: Int J Mol Med. 2014 Sep;34(3):880-5
references.pmid: 25016928
references.citation: Proc Natl Acad Sci U S A. 2009 May 19;106(20):8169-74
references.pmid: 19416807
references.citation: Pharmacol Rev. 1997 Sep;49(3):279-95
references.pmid: 9311024
references.citation: Chem Res Toxicol. 2008 Jan;21(1):70-83
references.pmid: 18052394
references.citation: BMC Res Notes. 2014 Sep 03;7:601
references.pmid: 25187308
references.citation: Am J Physiol. 1994 Aug;267(2 Pt 1):C367-74
references.pmid: 8074173